Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma

Cancer Immunity

Volumn 10, Issue , 2010, Pages

  Berman, David ^a   Parker, Susan M ^a   Siegel, Jonathan ^a   Chasalow, Scott D ^a   Weber, Jeffrey ^b   Galbraith, Susan ^a   Targan, Stephan R ^c   Wang, Hanlin L ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

CTLA 4; Gastrointestinal; Human; Immune related adverse event; Ipilimumab; Melanoma

Indexed keywords

BACTERIUM ANTIBODY; BUDESONIDE; CALGRANULIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; PLACEBO;

ADVANCED CANCER; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; COLITIS; DIARRHEA; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FECES LEVEL; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; INFLAMMATORY INFILTRATE; INOPERABLE CANCER; INTESTINE BIOPSY; INTESTINE FLORA; MAJOR CLINICAL STUDY; MELANOMA; MUCOSAL IMMUNITY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

EID: 78650428877     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297-339.
2. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-213
3. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614-2627
4. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A random-ized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-5598
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
6. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547.
7. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289
8. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Tar-gan SR. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126: 414-424.
9. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128: 2020-2028
10. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflamma-tory bowel disease. Nature 2007; 448: 427-434
11. Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol 2004; 20: 318-327
12. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an inte-grated clinical, molecular and serological classification of inflam-matory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A: 5-36
13. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grand-bastien B, Charrier G, Targan SR, Colombel JF, Poulain D. Anti- Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-791
14. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR. Selected loss of tolerance evidenced by Crohn's disease-associ-ated immune responses to auto- and microbial antigens. Gastroen-terology 2002; 123: 689-699
15. Geboes K. Histopathology of Crohn's disease and ulcerative colitis. In: Inflammatory bowel disease. 4th ed. Satsangi J, Sutherland LR. (Eds.) Edinburgh, London, Melbourne: Churchill Livingstone Elsevier; 2003; 255-276.
16. Guindi M, Riddell RH. Indeterminate colitis. J Clin Pathol 2004; 57: 1233-1244
17. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126: 1518-1532
18. Shidham VB, Chang CC, Shidham G, Ghazala F, Lindholm PF, Kampalath B, George V, Komorowski R. Colon biopsies for evalua-tion of acute graft-versus-host disease (A-GVHD) in allogeneic bone marrow transplant patients. BMC Gastroenterol 2003; 3: 5.
19. Xu CF, Zhu LX, Xu XM, Chen WC, Wu DP. Endoscopic diagnosis of gastrointestinal graft-versus-host disease. World J Gastroenterol 2008; 14: 2262-2267
20. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 524-534.
21. von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, Paraskeva P, Tekkis PP. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malig-nancy. Am J Gastroenterol 2007; 102: 803-813.
22. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metz-ker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Rønningen KS, Guja C, Ionescu-Tîrgoviste C, Savage DA, Max-well AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peter-son LB, Wicker LS, Todd JA, Gough SC. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-511
23. Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ. Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 2008; 31: 586-590.
24. Rodriguez-Bores L, Fonseca GC, Villeda MA, Yamamoto-Furusho JK. Novel genetic markers in inflammatory bowel disease. World J Gastroenterol 2007; 13: 5560-5570
25. Corydon TJ, Haagerup A, Jensen TG, Binderup HG, Petersen MS, Kaltoft K, Vestbo J, Kruse TA, Børglum AD. A functional CD86 polymorphism associated with asthma and related allergic disor-ders. J Med Genet 2007; 44: 509-515
26. Taurog JD. The mystery of HLA-B27: if it isn't one thing, it's another. Arthritis Rheum 2007; 56: 2478-2481
27. Fleischhauer K, Tanzarella S, Wallny HJ, Bordignon C, Traversari C. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-spe-cific HLA-A*0201+ cytotoxic T cell line. J Immunol 1996; 157: 787- 797
28. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12: 864-872.
29. Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calpro-tectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010; 47: 259-263
30. Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastro-enterol 2008; 14: 5584-5589
31. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404-413.
32. Thomas DG. Algorithm AS-36. Exact confidence limits for the odds ratio in a 2×2 table. Appl Statist 1971; 20: 105-110.